By Christiana Sciaudone
Investing.com -- Moderna (NASDAQ:) dropped 14% after AstraZeneca (NYSE:) and Oxford University said their vaccine candidate showed promise.
The AstraZeneca-Oxford vaccine, AZD1222, is safe and produced an immune response in early-stage clinical trials in healthy volunteers, Reuters reported, citing data from The Lancet. No serious side effects were reported.
JPMorgan (NYSE:) downgraded Moderna, which is working on a separate vaccine candidate, today on a high valuation, to neutral from overweight, The Street reported. Analyst Cory Kasimov boosted his one-year price target to $89 from $60.
Moderna has surged in recent months on vaccine news, quadrupling to more than $80 since March.
Moderna’s vaccine, mRNA-1273, elicited antibodies in all people tested in an initial safety trials, Bloomberg reported last week, though there was a high rate of side effects, with three of 45 people facing severe reactions. Moderna should begin a Phase 3 trial on July 27, The Street said.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Health - Latest - Google News
July 20, 2020 at 09:26PM
https://ift.tt/3eFHWWk
Moderna Sinks on AstraZeneca Covid-19 Vaccine Progress, JPMorgan Downgrade - Investing.com
Health - Latest - Google News
https://ift.tt/2zrj9Ud
Bagikan Berita Ini
0 Response to "Moderna Sinks on AstraZeneca Covid-19 Vaccine Progress, JPMorgan Downgrade - Investing.com"
Post a Comment